Lynx1 Capital Management LP Century Therapeutics, Inc. Transaction History
Lynx1 Capital Management LP
- $279 Million
- Q3 2024
A detailed history of Lynx1 Capital Management LP transactions in Century Therapeutics, Inc. stock. As of the latest transaction made, Lynx1 Capital Management LP holds 19,028 shares of IPSC stock, worth $19,408. This represents 0.01% of its overall portfolio holdings.
Number of Shares
19,028Holding current value
$19,408% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding IPSC
# of Institutions
67Shares Held
36.9MCall Options Held
8.7KPut Options Held
10.2K-
Bain Capital Life Sciences Investors, LLC Boston, MA5.41MShares$5.52 Million1.66% of portfolio
-
Vr Adviser, LLC New York, NY5.39MShares$5.5 Million0.95% of portfolio
-
Boxer Capital, LLC San Diego, CA3.9MShares$3.98 Million0.35% of portfolio
-
Casdin Capital, LLC New York, NY3.21MShares$3.28 Million0.43% of portfolio
-
Black Rock Inc. New York, NY2.9MShares$2.95 Million0.0% of portfolio
About Century Therapeutics, Inc.
- Ticker IPSC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,881,800
- Market Cap $60.1M
- Description
- Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...